A:

In 1982,

The U.S. Food and Drug Administration (FDA) recognized the lack of incentive for pharmaceutical companies to develop cures for rare diseases and established the Office of Orphan Product Development. This branch of the FDA provides incentives to companies that work toward curing rare diseases by exercising the rights given to them under the Orphan Drug Act of January 1983. One type of incentive is the orphan drug status, which provides tax reductions and the exclusive right to develop the cure for a specific condition for a period of seven years to companies attempting to cure rare diseases.

Developing drugs to treat the vast number of diseases in the world is a line of business that can lead to massive fortunes, but unfortunately not all developed drugs become the golden ticket. In the world pharmaceuticals, the largest amount of money can be made by developing drugs that become the standard for curing common diseases.

From a business perspective, having a large market ensures that a company can quickly recuperate the cost of development and can also realize the largest possible gain. For this reason, there is little incentive for pharmaceutical companies to develop cures for rare diseases - those that affect fewer than 200,000 people in the United States - because the small market and high cost associated with finding these types of cures discourages these companies from entering this market.

For related reading, check out Measuring The Medicine Makers.

RELATED FAQS
  1. What does it mean when a company in the drug sector has orphan drugs?

    Understand what it means when a company in the pharmaceutical industry has drugs within its portfolio that are designated ... Read Answer >>
  2. How does government regulation impact the drugs sector?

    Learn about how drugs are regulated by the U.S. government as well as the role of the Food and Drug Administration during ... Read Answer >>
  3. What does it mean that an investor faces binary outcomes when investing in drug companies?

    Learn why investments in biotech and drug companies can result in what are called binary outcomes, and understand why these ... Read Answer >>
  4. What process does a company need to follow to bring a new drug to market?

    Learn about the costly price of bringing new drugs to market. Discover why the pharmaceutical industry invests billions of ... Read Answer >>
  5. What are the major barriers to entry for new companies in the drugs sector?

    Find out why barriers to entry for U.S. drug companies are so high and how the Food and Drug Administration, or FDA, inhibits ... Read Answer >>
  6. What countries comprise the majority of the global drugs sector?

    Find out which countries are the largest producers of pharmaceutical products in the world and why the United States dominates ... Read Answer >>
Related Articles
  1. Investing

    Orphan Drug Rules Are Being Manipulated

    It may be the time to revamp the Orphan Drug Program amid concerns it's turning into a scam.
  2. Investing

    Senator Orders Investigation of Orphan Drug Abuse

    Iowa Senator Grassley ordered an inquiry into possible abuse of the Orphan Drug Act by drug makers.
  3. Investing

    3 of America's Most Expensive Drugs and Who Profits From Them

    Learn about orphan drugs that are some of the most expensive drugs in America. Read about the companies that manufacture these drugs.
  4. Investing

    Evaluating Pharmaceutical Companies

    Learn how to find a healthy pharmaceutical investment in a market full of weak drugs.
  5. Investing

    A Primer On The Biotech Sector

    Investing in the biotech sector can involve both huge losses and major gains.
  6. Insights

    How Pharmaceutical Companies Price Their Drugs

    Learn more about how pharmaceutical companies price drugs, why prices are often very high and why it can be difficult to settle on a suitable price.
  7. Personal Finance

    Senate Passes Bill to Expedite Drug Approval

    The US Senate just passed the biggest health reform bill since Obamacare.
  8. Insurance

    Why Do Prescription Drugs Cost So Much?

    In 1975, it cost about $100 million in 2005 dollars to develop one drug from the lab to FDA approval. By 2005, that figure was $1.3 billion.
  9. Investing

    Drug Approvals Fell to Six-Year Low in 2016

    New drug approvals dropped to modest levels in 2016 following highs in 2014 and 2015.
  10. Investing

    Cytori Scleroderma Wins Orphan Drug Status (CYTX)

    Cytori Therapeutics secured orphan drug status for its ECCS-50 drug to treat scleroderma.
RELATED TERMS
  1. Orphan Drug Credit

    A federal tax credit that provides an incentive for pharmaceutical ...
  2. Orphan Drug

    A drug or biological product that treats a rare condition or ...
  3. New Drug

    A new medication or therapy that has not been used before in ...
  4. Food And Drug Administration - FDA

    A government agency established in 1906 with the passage of the ...
  5. Abbreviated New Drug Application (ANDA)

    A written request to the U.S. Food and Drug Administration to ...
  6. New Drug Application (NDA)

    The final step formally taken by a drug sponsor, wherein it applies ...
Hot Definitions
  1. Frexit

    Frexit – short for "French exit" – is a French spinoff of the term Brexit, which emerged when the United Kingdom voted to ...
  2. Stop-Limit Order

    An order placed with a broker that combines the features of stop order with those of a limit order. A stop-limit order will ...
  3. Down Round

    A round of financing where investors purchase stock from a company at a lower valuation than the valuation placed upon the ...
  4. Keynesian Economics

    An economic theory of total spending in the economy and its effects on output and inflation. Keynesian economics was developed ...
  5. Portfolio Investment

    A holding of an asset in a portfolio. A portfolio investment is made with the expectation of earning a return on it. This ...
  6. Treynor Ratio

    A ratio developed by Jack Treynor that measures returns earned in excess of that which could have been earned on a riskless ...
Trading Center